NASDAQ:AGEN | Jotup

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

Retrieved on:

Mardi, mai 7, 2024

Under the terms of the agreement, Ligand will pay $75 million to Agenus at closing.

Key Points:

Under the terms of the agreement, Ligand will pay $75 million to Agenus at closing.
In addition, Ligand has the option to invest an additional $25 million on the same terms on a pro rata basis.
Ligand’s portion of the milestones related to these six programs has the potential to exceed $400 million, with royalties in the low single digits.
In addition, Ligand will also receive a 2.625% royalty on future global net sales generated by BOT/BAL.

Agenus Reports First Quarter 2024 Results

Retrieved on:

Mardi, mai 7, 2024

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024.

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024.
In a concurrent press release accompanying Agenus’ earnings announcement, a $100M royalty financing agreement between Ligand and Agenus was reported.
First Quarter 2024 Financial Overview:
We ended our first quarter 2024 with a cash and cash equivalent balance of $52.9 million, compared to $76.1 million on December 31, 2023.
Our cash used in operations for this first quarter was $38.2 million, compared to $40.6 million during the fourth quarter ended December 31, 2023.

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on:

Mercredi, mai 1, 2024

Biotechnology, Health, Oncology, Inc., Cancer

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2).

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2).
Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed.

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

Retrieved on:

Mercredi, avril 24, 2024

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Metadata, MSS, Colorectal cancer, Abstract, CRC, ASCO, Patient, Society, Inc., Cancer

The poster presentation is for a sub-analysis of the r/r MSS CRC cohort of the Phase 1b study.

Key Points:

The poster presentation is for a sub-analysis of the r/r MSS CRC cohort of the Phase 1b study.
This sub-analysis was done to determine whether treatment outcomes are correlated with specific sites of metastatic disease in patients with non-active liver mets.
Abstract Title: Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.
Data presented at the conference will be available to view in the publications section of the Agenus website ( https://agenusbio.com/publications ) following the ASCO Meeting.

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

Retrieved on:

Mardi, avril 23, 2024

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Inc., Cancer, Webcast, Agenus

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
Agenus executives will host a conference call and webcast at 8:30 a.m.
ET that morning to discuss the results and provide a corporate update.

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Retrieved on:

Vendredi, avril 12, 2024

Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, FDA, MSS, Food, Survival, CRC, OS, Biologics license application, Patient, BLA, Inc., Cancer, Pharmaceutical industry

These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' broad clinical development program.

Key Points:

These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' broad clinical development program.
The Phase 2 trial has completed enrollment and the company plans to discuss the encouraging interim results with the U.S. Food and Drug Administration (FDA).
“These results underscore the potential of BOT/BAL in metastatic CRC, the second leading cause of cancer mortality in the U.S.,” said Steven O’Day, M.D., Chief Medical Officer at Agenus.
This growing body of clinical evidence underscores the significant potential of BOT/BAL to transform the treatment landscape for difficult-to-treat solid tumors.

Agenus Announces Reverse Stock Split of Common Stock

Retrieved on:

Vendredi, avril 5, 2024

Infectious Diseases, Health, Oncology, Inc., Shareholder, Book, CUSIP, Security (finance), Equiniti, Index, Cancer, Eastern Time Zone

The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price of Agenus’ common stock to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Markets and to qualify for inclusion in the Russell Indices.

Key Points:

The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price of Agenus’ common stock to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Markets and to qualify for inclusion in the Russell Indices.
The reverse stock split affects all issued and outstanding shares of Agenus’ common stock.
The par value of the Agenus’ common stock will remain unchanged at $0.01 per share after the reverse stock split.
The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in Agenus’ equity, except to the extent that the reverse stock split results in some stockholders receiving cash in lieu of any fractional shares as described below.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on:

Jeudi, mars 14, 2024

Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
“In 2023, Agenus made significant advances across our BOT/BAL development program.
$25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Retrieved on:

Mercredi, mars 6, 2024

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CD96, Cancer, FC, Antibody, TIGIT, Inc., Vaccine

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.
In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies.
BMS-986442 (AGEN1777) leverages Agenus’ proprietary Fc-engineering platform to harness novel mechanisms of action that extend beyond the capabilities of conventional anti-TIGIT therapy.
However, conventional TIGIT antibodies have faced limitations with monotherapy activity in clinical settings,” said Dhan Chand, Ph.D., Vice President of Research.

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Mardi, mars 5, 2024

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Cancer, Compensated emancipation, Marketing, Business analytics, Inc.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.

Key Points:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively.
The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards to Nils Eckardt consist of (i) options to purchase 100,000 shares of Agenus common stock with a 10-year term, an exercise price equal to the closing price of Agenus' common stock on the Grant Date (February 1, 2024), and vesting over four years in equal annual installments and (ii) 50,000 restricted stock units that vest over three years in equal annual installments; provided that each equity award to Nils Eckardt is subject to him maintaining a service relationship with the company through the relevant vest date.
The awards to Kent Barnes consist of (i) options to purchase 100,000 shares of Agenus common stock with a 10-year term, an exercise price equal to the closing price of Agenus' common stock on the Grant Date (April 1, 2024), and vesting over four years in equal annual installments and (ii) 100,000 restricted stock units that vest over three years in equal annual installments; provided that each equity award to Kent Barnes is subject to him maintaining a service relationship with the company through the relevant vest date.